Stocks · News reference
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term
Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session. The company's market cap stands at $6.2 million. As per the news, the Q2 earnings report came out 2 days ago.
Filed: 2026-08-21 AccNo: 0001213900-26-092672 Size: 240 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing